Datroway demonstrated statistically significant OS & PFS improvement in 1L metastatic IO-ineligible TNBC patients in TROPION-Breast02 trial October 8, 2025
Supplemental BLA for Adjuvant ENHERTU Followed by THP Accepted in the US for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer October 8, 2025
86% Reduction in Tumor Burden Announced in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen October 7, 2025
Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in TNBC September 30, 2025
Enhertu demonstrated statistically significant improvement in invasive DFS vs. T-DM1 in DESTINY-Breast05 Ph III trial in patients with high-risk early breast cancer following neoadjuvant therapy September 30, 2025
Enhertu + pertuzumab granted Priority Review in the US as 1L treatment for patients with HER2-positive metastatic breast cancer September 30, 2025
FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer September 30, 2025
Avenzo Therapeutics Announces $60 Million Series B Financing to support pipeline advancement of oncology drug candidates September 23, 2025
Arvinas and Pfizer plan to jointly select third party for the out-licensing and commercialization of vepdegestrant September 23, 2025
SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer September 23, 2025
Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti September 23, 2025
Positive Ph 3 Results Show Giredestrant Significantly Improved PFS in ER-Positive Advanced Breast Cancer September 23, 2025
Ph 3 Trial of BNT323/DB-1303 Met Primary Endpoint of PFS in HER2+ve Metastatic or Unresectable Breast Cancer September 10, 2025
HERTHENA-Breast04 Ph 3 Trial of Patritumab Deruxtecan Initiated for Metastatic HR+ve, HER2-neg Breast Cancer Previously Treated with Endocrine Therapy September 3, 2025
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer September 3, 2025
Verzenio® (abemaciclib) increases OS in HR+, HER2-, high-risk early breast cancer with two years of therapy September 3, 2025
NDA Submission of Gedatolisib in PIK3CA WT Cohort in HR+/HER2- Advanced Breast Cancer to be Initiated Under FDA’s RTOR Program September 3, 2025
ENHERTU® Approved in Japan for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy September 3, 2025
DATROWAY® Approved in China for Patients with Previously Treated Metastatic HR+ve, HER2-neg Breast Cancer September 3, 2025
Incyclix Bio Secures $11.25M Series B Extension for Ph 1/2 Trial of INX-315 in CDK4/6i-Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors August 26, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers August 19, 2025
First Patient Dosed in Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs August 19, 2025
